Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PBMs Could Reduce Rx Spending By 25% Under GOP Medicare Plan - CBO

Executive Summary

The Congressional Budget Office estimates that pharmacy benefit management companies will generate a 25% reduction in retail drug costs under the House Medicare drug benefit bill.

You may also be interested in...



AARP Engages In Medicare Rx Debate; Focus Shifts To Senate

AARP is concerned about the use of actuarial equivalence in the House Medicare Rx drug bill.

Medicare Drug Benefit Could Use Medicaid Price As Ceiling - Schondelmeyer

Congress should consider using Medicaid prices as a ceiling for a federal Medicare drug benefit program, University of Minnesota PRIME Institute Director Stephen Schondelmeyer, PhD, suggested during a June 13 House Ways & Means Committee hearing.

Medco/Reader's Digest Consumer PBM Plan Offers 18% Discount On Mail Rxs

The Merck-Medco/Reader's Digest consumer discount plan offers enrollees an average discount of 18% for mail-service prescriptions, Merck-Medco said.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS036279

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel